Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating NX-5948 bexobrutideg, a BTK degrader, in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with both covalent and non-covalent BTK inhibitors and a BCL-2 inhibitor. This study aims to understand how well NX-5948 works, how safe it is, and how the drug behaves in the bloodstream over time. Participants will receive NX-5948 orally once daily in continuous 28-day cycles until their cancer worsens or other reasons require stopping treatment. The study is open-label and single-group, meaning all participants receive the study drug. If a participant stops treatment without disease progression, they will continue regular cancer check-ups until progression occurs. During the study, participants will have regular health and cancer assessments, including monitoring of adverse events, laboratory tests, and quality of life questionnaires. The primary outcome is the objective response rate assessed up to approximately five years. Safety and pharmacokinetics will be monitored, and participation can last up to five years or longer if the disease remains stable.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and changes in disease activity of an investigational drug called ABBV-706 compared to standard treatments for relapsed or refractory small cell lung cancer SCLC, a fast-growing cancer that often spreads early to other parts of the body. This Phase 3 trial involves about 531 adult participants worldwide and aims to assess how ABBV-706 works against current standard care options including topotecan, lurbinectedin, or amrubicin. Participants with SCLC will be randomly assigned to receive either ABBV-706 or one of the standard care treatments. ABBV-706 and the comparator drugs are given through intravenous infusion, with topotecan also available orally. The entire study is expected to last approximately 53 months, during which participants will receive their assigned treatment as part of this extended timeframe. During the study, participants will attend regular visits at a hospital or clinic for medical assessments, which include blood tests, scans, and questionnaires to monitor disease progression and treatment effects. Researchers will measure outcomes such as overall response rate, overall survival, progression-free survival, and quality of life changes. Safety and adverse events will be tracked throughout the study duration of up to 53 months.
Actively Recruiting
Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.
Actively Recruiting
Researchers are evaluating how well the combination of enfortumab vedotin and pembrolizumab works compared to the standard treatment of concurrent chemoradiotherapy for patients with muscle-invasive bladder cancer that has not spread beyond the bladder. This phase 3 study focuses on adults who are either ineligible for or have chosen not to undergo bladder removal surgery cystectomy. The goal is to find effective bladder preservation treatments for this condition. Participants in the study will receive either the combination of enfortumab vedotin and pembrolizumab or the standard concurrent chemoradiotherapy. Enfortumab vedotin is given as an intravenous infusion on Days 1 and 8 of every 3-week cycle, for up to 9 cycles. Pembrolizumab is given as an intravenous infusion on Day 1 of every 3-week cycle, for up to 17 cycles. The chemoradiotherapy involves radiation to the bladder and possibly pelvic nodes over a maximum of 6.5 weeks, with chemotherapy drugs administered intravenously during radiation. During the study, participants will be closely monitored through various evaluations including bladder-intact event free survival and overall survival over several years. Researchers will assess clinical response, metastasis-free survival, time to cystectomy, and adverse events related to the treatments. The monitoring period includes up to approximately 60 months of follow-up to gather comprehensive outcomes on treatment effectiveness and safety.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
Actively Recruiting
Researchers are evaluating the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy for adults with Extensive Stage Small Cell Lung Cancer ES-SCLC who have not experienced tumor progression after initial treatment with carboplatin, etoposide, and atezolizumab. This open-label Phase 12 study aims to determine the right dose and assess safety and effectiveness of this combination therapy. The study is led by Genprex, Inc. and includes a dose selection phase followed by a safety and efficacy phase. In the dose selection phase Phase 1, patients received quaratusugene ozeplasmid intravenously every 21 days at increasing doses combined with atezolizumab given intravenously every 21 days to find the recommended dose for Phase 2. In Phase 2, patients receive the recommended dose of quaratusugene ozeplasmid with atezolizumab or with atezolizumab plus hyaluronidase-tqjs administered subcutaneously every 21 days. Treatment continues until the disease progresses or unacceptable side effects occur. Participants will have regular assessments including monitoring for side effects using standardized criteria, blood tests to check kidney, liver, and blood cell function, and cardiac evaluations. Researchers will measure outcomes such as the maximum tolerated dose, progression-free survival at 18 weeks, overall survival, and pharmacokinetics of the study drug. Participation lasts through the treatment period and follow-up evaluations to monitor safety and effectiveness, with the primary completion expected by December 2027.
Actively Recruiting
Researchers are evaluating radiation therapy with or without the chemotherapy drug cisplatin in patients with stage III-IVA squamous cell carcinoma of the head and neck who have had surgery to remove their tumor. This phase II trial aims to understand if adding cisplatin to radiation therapy improves disease-free survival, especially in relation to different types of p53 gene mutations, which might affect treatment outcomes. The study also looks at side effects and explores genetic changes that could influence new treatments. Participants are randomly assigned to one of two groups one group receives intensity-modulated radiation therapy IMRT alone once daily, five days a week for six weeks, while the other group receives the same radiation schedule combined with weekly intravenous cisplatin over 1 to 2 hours for six weeks. After completing treatment without disease progression or unacceptable side effects, patients enter a follow-up period lasting up to 10 years. During the study, participants undergo assessments including surgical tumor tissue analysis for p53 mutations, imaging tests to exclude distant disease, and regular health evaluations. After treatment, patients are monitored every six months for three years and then annually for seven more years to track disease recurrence or new tumors. The main outcome measured is disease-free survival, focusing on the time from randomization to recurrence, second primary tumor, or death.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.
1-10 of 13
1